Summary
Global Markets Direct’s, ‘NAL Pharmaceuticals Ltd. - Product Pipeline Review - 2016’, provides an overview of the NAL Pharmaceuticals Ltd.’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by NAL Pharmaceuticals Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of NAL Pharmaceuticals Ltd.
- The report provides overview of NAL Pharmaceuticals Ltd. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses NAL Pharmaceuticals Ltd.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features NAL Pharmaceuticals Ltd.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate NAL Pharmaceuticals Ltd.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for NAL Pharmaceuticals Ltd.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding NAL Pharmaceuticals Ltd.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
NAL Pharmaceuticals Ltd. Snapshot 6
NAL Pharmaceuticals Ltd. Overview 6
Key Information 6
Key Facts 6
NAL Pharmaceuticals Ltd. - Research and Development Overview 7
Key Therapeutic Areas 7
NAL Pharmaceuticals Ltd. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
NAL Pharmaceuticals Ltd. - Pipeline Products Glance 12
NAL Pharmaceuticals Ltd. - Early Stage Pipeline Products 12
Preclinical Products/Combination Treatment Modalities 12
Discovery Products/Combination Treatment Modalities 13
NAL Pharmaceuticals Ltd. - Unknown Stage Pipeline Products 14
Unknown Products/Combination Treatment Modalities 14
NAL Pharmaceuticals Ltd. - Drug Profiles 15
pegfilgrastim 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
montelukast sodium 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
diclofenac sodium 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
donepezil hydrochloride 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
donepezil hydrochloride Patch 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
formoterol fumarate 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
galantamine hydrobromide 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
indomethacin 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
ketoprofen 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
levocetirizine dihydrochloride 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
NAL-3216 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
NAL-3221 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
NAL-3223 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
nicotine bitartrate 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
rizatriptan benzoate 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
sildenafil citrate 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
sufentanil citrate 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
tadalafil 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
tulobuterol 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
NAL Pharmaceuticals Ltd. - Pipeline Analysis 34
NAL Pharmaceuticals Ltd. - Pipeline Products by Target 34
NAL Pharmaceuticals Ltd. - Pipeline Products by Route of Administration 36
NAL Pharmaceuticals Ltd. - Pipeline Products by Molecule Type 37
NAL Pharmaceuticals Ltd. - Pipeline Products by Mechanism of Action 38
NAL Pharmaceuticals Ltd. - Dormant Projects 39
NAL Pharmaceuticals Ltd. - Locations And Subsidiaries 40
Head Office 40
Appendix 41
Methodology 41
Coverage 41
Secondary Research 41
Primary Research 41
Expert Panel Validation 41
Contact Us 41
Disclaimer 42
List of Tables
NAL Pharmaceuticals Ltd., Key Information 6
NAL Pharmaceuticals Ltd., Key Facts 6
NAL Pharmaceuticals Ltd. - Pipeline by Indication, 2016 8
NAL Pharmaceuticals Ltd. - Pipeline by Stage of Development, 2016 10
NAL Pharmaceuticals Ltd. - Monotherapy Products in Pipeline, 2016 11
NAL Pharmaceuticals Ltd. - Preclinical, 2016 12
NAL Pharmaceuticals Ltd. - Discovery, 2016 13
NAL Pharmaceuticals Ltd. - Unknown, 2016 14
NAL Pharmaceuticals Ltd. - Pipeline by Target, 2016 35
NAL Pharmaceuticals Ltd. - Pipeline by Route of Administration, 2016 36
NAL Pharmaceuticals Ltd. - Pipeline by Molecule Type, 2016 37
NAL Pharmaceuticals Ltd. - Pipeline Products by Mechanism of Action, 2016 38
NAL Pharmaceuticals Ltd. - Dormant Developmental Projects,2016 39
List of Figures
NAL Pharmaceuticals Ltd. - Pipeline by Top 10 Indication, 2016 8
NAL Pharmaceuticals Ltd. - Pipeline by Stage of Development, 2016 10
NAL Pharmaceuticals Ltd. - Monotherapy Products in Pipeline, 2016 11
NAL Pharmaceuticals Ltd. - Pipeline by Top 10 Target, 2016 34
NAL Pharmaceuticals Ltd. - Pipeline by Top 10 Route of Administration, 2016 36
NAL Pharmaceuticals Ltd. - Pipeline by Molecule Type, 2016 37
NAL Pharmaceuticals Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2016 38
